Cat.No：GM-88046MAB
Product ：Anti-IL17A hIgG4 Reference Antibody (Ixebio)
Cat.No：GM-88046MAB
Product ：Anti-IL17A hIgG4 Reference Antibody (Ixebio)
GM-88046MAB-1mg / 1 mg
GM-88046MAB-5mg / 5 mg
GM-88046MAB-25mg / 5 mg * 5 vials
GM-88046MAB-50mg / 50 mg
GM-88046MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Species Reactivity | Human |
Clone | ixekizumab |
Source/Isotype | Human IgG4(S228P), kappa |
Application | Flow Cytometry |
Specificity | Detects IL17A |
Gene | IL17A |
Other Names | CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17 |
Gene ID | 3605 (human) |
Background | IL-17A encodes a Proinflammatory cytokine protein that, together with IL-17A, participates in immune responses and inflammation. The IL-17 family also includes members such as IL17F and IL17C, but IL-17A is often regarded as one of the core driver molecules of this pathway. Il-17a activates downstream NF-κb, MAPK, C/EBP, and other signaling pathways by binding to the IL-17R (including subtypes of IL-17RA, IL-17RC, etc.) complex, and the IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R It induces the expression of a variety of chemokines, cytokines (such as IL-6, IL-8, GM-CSF) and chemokine proteins, promoting neutrophil recruitment and amplification of inflammation. Ixekizumab is a fully humanized monoclonal antibody (MAB) that targets IL-17A. By specifically binding to IL-17A, the interaction between IL-17A and Il-17 receptor is blocked, thereby inhibiting the expression of downstream pro-inflammatory factors, chemokines and inflammatory cells, and reducing inflammatory response and immune damage. |
Storage | Store at 2-8°C short term (1-2 weeks). Store at ≤ -20°C long term.Avoid repeated freeze-thaw. |
Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Cat.No：GM-88046MAB
Product ：Anti-IL17A hIgG4 Reference Antibody (Ixebio)
GM-88046MAB-1mg / 1 mg
GM-88046MAB-5mg / 5 mg
GM-88046MAB-25mg / 5 mg * 5 vials
GM-88046MAB-50mg / 50 mg
GM-88046MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Species Reactivity | Human |
Clone | ixekizumab |
Source/Isotype | Human IgG4(S228P), kappa |
Application | Flow Cytometry |
Specificity | Detects IL17A |
Gene | IL17A |
Other Names | CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17 |
Gene ID | 3605 (human) |
Background | IL-17A encodes a Proinflammatory cytokine protein that, together with IL-17A, participates in immune responses and inflammation. The IL-17 family also includes members such as IL17F and IL17C, but IL-17A is often regarded as one of the core driver molecules of this pathway. Il-17a activates downstream NF-κb, MAPK, C/EBP, and other signaling pathways by binding to the IL-17R (including subtypes of IL-17RA, IL-17RC, etc.) complex, and the IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R/IL-17R It induces the expression of a variety of chemokines, cytokines (such as IL-6, IL-8, GM-CSF) and chemokine proteins, promoting neutrophil recruitment and amplification of inflammation. Ixekizumab is a fully humanized monoclonal antibody (MAB) that targets IL-17A. By specifically binding to IL-17A, the interaction between IL-17A and Il-17 receptor is blocked, thereby inhibiting the expression of downstream pro-inflammatory factors, chemokines and inflammatory cells, and reducing inflammatory response and immune damage. |
Storage | Store at 2-8°C short term (1-2 weeks). Store at ≤ -20°C long term.Avoid repeated freeze-thaw. |
Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
